Systemic Treatment with a KLK5 Inhibitor Shows Efficacy in a Murine Model of Netherton Syndrome

    July 2024 in “ Journal of Investigative Dermatology ”
    Hiroyuki Takahashi, Hajime Yano, D. Nishimiya, Norikazu Gotoh, Naoko Ubukata, Sonoko Takada, Eiko Suzuki, Y. Shibaya, Satoshi Yamaguchi, Giorgio Senaldi, T. Nishizawa
    Studysummary This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Systemic treatment with DS77754007, a specific KLK5 inhibitor, demonstrated significant efficacy in improving skin manifestations in a mouse model of Netherton Syndrome (NS). The study involved C57BL6 mice with a homozygous mutation in the Spink5 gene, treated with DS77754007 or various antibodies over 4 weeks. Results showed that the three item severity (TIS) score was significantly lower in mice treated with DS77754007 compared to those treated with vehicle or anti-IL-4/13R, anti-TNFa antibodies. Although anti-IL-17A antibody also reduced the TIS score, DS77754007 was more effective, suggesting that systemic KLK5 inhibition could be a promising treatment for NS.
    Discuss this study in the Community →